Skip Navigation
Menu
Original Research |1 June 1997

Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin

Adrian M. Senderowicz, MD; Ellen Vitetta, PhD; Donna Headlee, RN; Victor Ghetie, PhD; Jonathan W. Uhr, MD; William D. Figg, PharmD; Richard M. Lush, PhD; Maryalice Stetler-Stevenson, MD, PhD; Glenn Kershaw, MD; Douglas W. Kingma, MD; Elaine S. Jaffe, MD; Edward A. Sausville, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Copyright ©2004 by the American College of Physicians
2004
  • From the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas. Grant Support: Extramural portions of the study were supported by National Institutes of Health grants CA28149 and CA41081. Requests for Reprints: Edward A. Sausville, MD, PhD, Developmental Therapeutics Program, National Cancer Institute, Executive Plaza North, Suite 843, 6130 Executive Boulevard, Rockville, MD 20852. Current Author Addresses: Dr. Senderowicz and Ms. Headlee: Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892.
×
FULL TEXT
CD19, CD20, CD21, CD22: B-cell surface markers frequently expressed on the surface of B-cell tumors. The immunotoxin used in our patient is directed against CD22.
EBER-1: Epstein-Barr encoded RNA.
Immunotoxin: A drug formed by chemical linkage of an antibody to a toxin.
RFB4-dgA: The immunotoxin used in our patient; it consists of the murine monoclonal antibody RFB4, which is linked to the deglycosylated A-chain of ricin, a plant toxin.
Vascular leak syndrome: A side effect of immunotoxin treatment that consists of nontargeted damage to endothelial cells and manifests as hypoalbuminemia and edema in its mild form.
Transplant recipients have an increased risk for post-transplantation lymphoproliferative diseases associated with Epstein-Barr virus. The incidence of such diseases is 1% in recipients of kidney transplants, 2.4% in recipients of heart or heart and lung transplants, 1% in recipients of liver transplants, and 0.6% in recipients of pancreas transplants [1]. Morphologic criteria distinguish at least three types of lymphoproliferative diseases: polyclonal B-cell or plasma cell hyperplasia; polymorphic B-cell hyperplasia and lymphoma, which are usually monoclonal; and monomorphic B-cell lymphoma [2, 3]. Particularly in polyclonal forms of disease, a decrease in the intensity of immunosuppressive therapy (for example, a decrease in the cyclosporine dose) with or without antiviral treatment leads to long-term clinical improvement [2]. If decreased immunosuppression as a therapeutic strategy is not successful, patients may receive chemotherapy; these patients, however, have a poor prognosis. The optimal management of patients whose disease progresses after chemotherapy is unknown [1].
FULL TEXT
PDF
Not Available
Citations
Citation

Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, et al. Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin. Ann Intern Med. ;126:882–885. doi: 10.7326/0003-4819-126-11-199706010-00005

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1997;126(11):882-885.

DOI: 10.7326/0003-4819-126-11-199706010-00005

47 Citations

Related Articles
Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant
Annals of Internal Medicine; 169 (10): 674-683
Twelve-Month Outcomes After Transplant of Hepatitis C–Infected Kidneys Into Uninfected Recipients: A Single-Group Trial
Annals of Internal Medicine; 169 (5): 273-281
Transplanting Hepatitis C Virus–Infected Versus Uninfected Kidneys Into Hepatitis C Virus–Infected Recipients: A Cost-Effectiveness Analysis
Annals of Internal Medicine; 169 (4): 214-223
Opioid Use Disorder, Stigma, and Transplantation: A Call to Action
Annals of Internal Medicine; 169 (3): 188-189
View MoreView Less

Related Topics
Hematology/Oncology
Leukemia/Lymphoma

Hematology/Oncology, Leukemia/Lymphoma.

PubMed Articles
Vasoreactivity to Acetylcholine During Porcine Kidney Perfusion for the Assessment of Ischemic Injury.
J Surg Res 2019;
The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.
Biol Blood Marrow Transplant 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×